^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

Excerpt:
...18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status...The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001)...Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001).
DOI:
10.1016/S1470-2045(18)30700-9
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab

Excerpt:
...RFS at 24 months in patients with pNR and being subsequently treated with adjuvant nivolumab+optional radiotherapy (or dabrafenib/trametinib if BRAFV600E pos. ...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Published date:
08/25/2021
Excerpt:
Combi-ICI showed prolonged mOS with sustainable IC and EC responses. Despite the initially increased efficacy, Combi-TT responses at 12 months were low. Combi-ICI appeared superior to Combi-TT for OS and PFS in BRAFV600 patients
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Three cases of BRAF-mutant melanoma with divergent differentiation masquerading as sarcoma

Published date:
06/30/2022
Excerpt:
A 57-year-old woman presented with abdominal pain. Eighteen months prior to this presentation she had BRAF V600E mutant metastases of cutaneous melanoma, involving soft tissues, vertebrae and the brain. She had obtained a complete radiological response with induction checkpoint inhibitor therapy, using ipilimumab and nivolumab.
DOI:
10.32074/1591-951X-771
Evidence Level:
Sensitive: C4 – Case Studies
Title:

P-111 Tumor lysis syndrome induced by BRAF/MEK double blockade in a patient with metastatic melanoma

Published date:
04/15/2021
Excerpt:
CONTRADICTING EVIDENCE: A 51-year-old woman....The pleural biopsy confirmed the diagnosis as pleural metastasis of BRAFV600E mutated melanoma….Although melanoma treatment was changed to PD-1 and CTLA-4 combination blockade with nivolumab (80mg/body) and ipilimumab (3mg/kg) for second line therapy, and was changed again to BRAF/MEK double blockade with dabrafenib (300mg/day) and trametinib (2mg/day) for third line therapy, she eventually died of respiratory failure due to exacerbation of melanoma lung metastases.
Evidence Level:
Sensitive: C4 – Case Studies
New
Source:
Title:

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

Excerpt:
Patient 5 (V600EBRAF) presented with extensive metastatic disease and was enrolled in the CheckMate 067 trial (anti-PD-1 antibody nivolumab alone versus anti-CTLA-4 antibody ipilimumab alone versus combination of the two)...Follow up CT scans also demonstrated tumour shrinkage (Fig. 3a). The PET scan performed on day 188 showed no metabolically active lesions and the tumour seen on CT scans from day 1 of treatment (Fig. 3b red arrow) was resolved on day 263 (Fig 3c).
DOI:
10.1038/srep11198